Picture of Trans Lux logo

TNLX — Trans Lux News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro Cap

Australia's Telix Pharma rises on FDA nod for kidney cancer midstage study

** Australian biopharma firm Telix Pharmaceuticals  TLX.AX 
rises as much as 10.4% to A$7.25, biggest intraday pct jump
since June 25
    ** Says https://telixpharma.com/investors/# U.S. Food and
Drug Administration accepted its Investigational New Drug
Application to conduct clinical study of TLX's investigational
kidney cancer therapy, TLX250
    ** Expects to enrol 29 patients in phase-2 study to
determine efficacy of the therapy to treat kidney tumours 
    ** TLX hits highest since Sept 3; set for a second straight
gain session
    ** Stock fourth-biggest percentage gainer in the ASX All
Ordinaries index  .AORD 
    ** TLX up 73.8% this year, as of last close, vs a 12.8%
increase in the ASX All Ordinaries index  .AORD 

 (Reporting by Sameer Manekar in Bengaluru)
 ((Sameer.Manekar@thomsonreuters.com;))

Recent news on Trans Lux

See all news